Abstract:OBJECTIVE To evaluate the efficacy and economy of cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam in treatment of gram-negative bacteria infections.METHODS By means of non-random observational study, the data of antibiotics therapy were collected from 322 patients with gram-negative bacteria infections who were hospitalized from Jan 1, 2012 to May 11, 2016 and were treated with cefoperazone-sulbactam, imipenem-cilastatin, and piperacillin-tazobactam.The pharmacoeconomics were evaluated with the use of cost-effectiveness analysis method.RESULTS The data were obtained from a large sample, non-random, and active surveillance study, the between-group covariate imbalance phenomenon existed in the original data, and the between-group covariate imbalance phenomenon was remarkably improved after they were matched by using propensity scoring method.After the matching, the economic analysis of costs of target antibiotics was carried out after the matching.As compared with cefoperazone-sulbactam and imipenem-cilastatin, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 39.15 yuan, 51.02 yuan, 52.61 yuan, and 40.09 yuan, respectively;while the imipenem-cilastatin needed 75.54 yuan, 81.28 yuan, 83.39 yuan, and 72.15 yuan respectively.As compared with cefoperazone-sulbactam and piperacillin-tazobactam, cefoperazone-sulbactam that obtained every 1% clinical efficacy, microbial efficacy, comprehensive effect, and 30-day survival rate only needed 36.94 yuan, 46.80 yuan, 48.40 yuan, and 33.42 yuan, respectively;while piperacillin-tazobactam needed 99.99 yuan, 117.64 yuan, 121.21 yuan, and 95.23 yuan, respectively.The four cost-effectiveness analyses showed that cefoperazone-sulbactam had obvious economic advantages.Under the circumstances of the same efficacy, the cost of cefoperazone-sulbactam was 1/3~1/2 of the cost of piperacillin-tazobactam and imipenem-cilastatin.The sensitivity analysis based on the 95% confidence limit of efficacy showed that the conclusion remained true.CONCLUSION Cefoperazone-sulbactam has more cost-effectiveness advantages on treatment of the gram-negative bacteria (including multidrug-resistant organisms) infections.

Clinical Analysis of Etimicin Combined with Cefuroxime Axetil in the Treatment of Patients with Community-Acquired Pneumonia from 14 to 18 Years Old

A multicenter study on the in vitro antibacterial activity of cefoselis against common clinical bacteria

Causative Agent Distribution and Antibiotic Therapy Assessment among Adult Patients with Community Acquired Pneumonia in Chinese Urban Population.

Clinical evaluation on the empirical treatment of community acquired pneumonia

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Evaluation on Efficacy of Initial Empirical Antimicrobial Therapy for Patients with Community Acquired Pneumonia in Emergency Ward

Meta-analysis of the Efficacy of Oral Antibiotics Treatment with Parenteral Antibiotics Treatment in Commu-Nity Acquired Pneumonia Children

Analysis of the Medication of Elderly Patients with Community-acquired Pneumonia in Our Hospital from 2010 to 2012

Efficacy and Safety of Intravenous Moxifloxacin Versus Cefoperazone with Azithromycin in the Treatment of Community Acquired Pneumonia

Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward.

A multicenter,randomized,and double-blind controlled clinical trial of cefepime in treatment of acute bacterial infections

Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia Coli and Klebsiella Pneumoniae: A Multicenter Study in China

Improvement in Clinical and Economic Outcomes with Empiric Antibiotic Therapy Covering Atypical Pathogens for Community-Acquired Pneumonia Patients: a Multicenter Cohort Study.

Curative Effect Analysis of Cefoxitin Sodium in the Treatment of Senile Bacterial Lower Respiratory Tract Infection

Analysis of Clinical Efficacy of Different Initial Antimicrobial Treatment in Healthcare Associated Pneumonia Patients in Emergency Department.

Efficacy of cefepime on the treatment of senile with lower respiratory infections

Cefepime Combined with Amoxicillin/clavulanic Acid: a New Choice for the KPC-producing K. Pneumoniae Infection

Clinical evaluation of 377 cases of etimicin sulfate on bacterial infections

Study on Etiology of Community-Acquired Pneumonia in Shanghai During 2001-2003

Comparative study on cefprozil and cefaclor in the treatment of respiratory tract infections

Comparative investigation into the current therapeutic strategy for community acquired pneumonia with the suggested protocols by national and international guidelines